Hansa Biopharma (HNSA) announced that Hitto Kaufmann has been appointed as Hansa’s chief scientific officer, or CSO, effective December 1. As CSO, Kaufmann will be responsible for all research, early development, translational and manufacturing activities. He will report to president and CEO Soren Tulstrup and serve as a member of Hansa’s executive committee. Kaufmann joins Hansa from Pieris Pharmaceuticals (PIRS) where he has served as chief scientific officer since 2019.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PIRS: